[1] |
刘辉,冯永文,姚咏明. 脓毒症治疗新进展[J/OL]. 中华重症医学电子杂志,2018, 4(4): 299-303.
|
[2] |
Dantes RB, Lauren E. Combatting Sepsis: A Public Health Perspective[J]. Clin Infect Dis, 2018, 67(8): 1300-1302.
|
[3] |
Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations[J]. Am J Respir Crit Care Med, 2016, 193(3): 259-272.
|
[4] |
Teggert A, Datta H, Ali Z. Biomarkers for Point-of-Care Diagnosis of Sepsis[J]. Micromachines (Basel), 2020, 11(3): 286.
|
[5] |
单亮,修建荣,李秀,等. 脓毒症早期诊断生物标志物的再评价[J]. 中华危重病急救医学,2015, 27(6): 538-540.
|
[6] |
Tschaikowsky K, Hedwig-Geissing M, Schmidt J, et al. Lipopolysaccharide-binding protein for monitoring of postoperative sepsis: complemental to C-reactive protein or redundant?[J]. PLOs One, 2011, 6(8): e23615.
|
[7] |
Tschaikowsky K, Hedwig-Geissing M, Braun GG, et al. Predictive value of procalcitonin, interleukin-6, and C-reactive protein for survival in postoperative patients with severe sepsis[J]. J Crit Care, 2011, 26(1): 54-64.
|
[8] |
Parlato M, Cavaillon JM. Host Response Biomarkers in the Diagnosis of Sepsis: A General Overview[J]. Methods Mol Biol, 2015, 1237: 149-211.
|
[9] |
Shirali AS, Wu JX, Zhu CY, et al. The role of serum procalcitonin in predicting bacterial sepsis in patients with hypothyroidism[J]. J Clin Endocrinol Metab, 2019, 104(12): 5915-5922.
|
[10] |
Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis[J]. Crit Care Med, 2006, 34(7): 1996-2003.
|
[11] |
Tang BM, Eslick GD, Craig JC, et al. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis[J]. Lancet Infect Dis, 2007, 7(3): 210-217.
|
[12] |
Vincent JL, Nuffelen MV, Lelubre C. Host Response Biomarkers in Sepsis: The Role of Procalcitonin[J]. Methods Mol Biol, 2015, 1237: 213-224.
|
[13] |
Arora S, Singh P, Singh PM, et al. Procalcitonin Levels in Survivors and Nonsurvivors of Sepsis: Systematic Review and Meta-Analysis[J]. Shock, 2015, 43(3): 212-221.
|
[14] |
Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis[J]. Crit Care, 2013, 17(6): R291.
|
[15] |
Andriolo BN, Andriolo RB, Salomão R, et al. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock[J]. Cochrane Database Syst Rev, 2017, 1(1): CD010959.
|
[16] |
Rodríguez-Gaspar M, Santolaria F, Jarque-López A, et al. Prognostic value of cytokines in SIRS general medical patients[J]. Cytokine, 2001, 15(4): 232-236.
|
[17] |
Gaïni S, Koldkjaer OG, Pedersen C, et al. Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study[J]. Crit Care, 2006, 10(2): R53.
|
[18] |
Reyes CS, García-Muñoz F, Reyes D, et al. Role of cytokines (interleukin-1beta, 6, 8, tumour necrosis factor-alpha, and soluble receptor of interleukin-2) and C-reactive protein in the diagnosis of neonatal sepsis[J]. Acta Paediatr, 2003, 92(2): 221-227.
|
[19] |
Jekarl DW, Lee S-Y, Lee J, et al. Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis[J]. Diagn Microbiol Infect Dis, 2013, 75(4): 342-347.
|
[20] |
Hu P, Chen Y, Pang J, et al. Association between IL-6 polymorphisms and sepsis[J]. Innate Immun, 2019, 25(8): 465-472.
|
[21] |
Tamayo E, Fernández A, Almansa R, et al. Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock[J]. Eur Cytokine Netw, 2011, 22(2): 82-87.
|
[22] |
Guillaume M, Marie-Emmanuelle F, Fabienne V, et al. The anti-inflammatory response dominates after septic shock: association of low monocyte HLA-DR expression and high interleukin-10 concentration[J]. Immunol Lett, 2004, 95(2): 193-198.
|
[23] |
Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock[J]. Am J Respir Crit Care Med, 2008, 178(3): 276-282.
|
[24] |
Winkler MS, Rissiek A, Priefler M, et al. Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: A diagnostic tool for immunosuppression?[J]. PLOs One, 2017, 12(8): e0182427.
|
[25] |
Fabienne V, Sylvie T, Anne-Lise D, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: Correlation with severity and secondary septic shock[J]. Crit Care Med, 2007, 35(8): 1910-1917.
|
[26] |
Landelle C, Lepape A, Voirin N, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock[J]. Intensive Care Med, 2010, 36(11): 1859-1866.
|
[27] |
Meisel C, Schefold JC, Pschowski R, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial[J]. Am J Respir Crit Care Med, 2009, 180(7): 640-648.
|
[28] |
Wu J, Zhou L, Liu J, et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1): R8.
|
[29] |
Lewis SM, Treacher DF, Bergmeier L, et al. Plasma from patients with sepsis up-regulates the expression of CD49d and CD64 on blood neutrophils[J]. Am J Respir Cell Mol Biol, 2009, 40(6): 724-732.
|
[30] |
Dai J, Jiang W, Min Z, et al. Neutrophil CD64 as a diagnostic marker for neonatal sepsis: Meta-analysis[J]. Adv Clin Exp Med, 2017, 26(2): 327-332.
|
[31] |
Livaditi O, Kotanidou A, Psarra A, et al. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis[J]. Cytokine, 2006, 36(5/6): 283-290.
|
[32] |
Aikaterini D, Olivier P, Zaina K, et al. Serial determinations of neutrophil CD64 expression for the diagnosis and monitoring of sepsis in critically ill patients[J]. Clin Infect Dis, 2014, 58(6): 820-829.
|
[33] |
Lemarié J, Barraud D, Gibot S. Host Response Biomarkers in Sepsis: Overview on sTREM-1 Detection[J]. Methods Mol Biol, 2015, 1237: 225-239.
|
[34] |
Wu Y, Wang F, Fan X, et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis[J]. Crit Care, 2012, 16(6): R229.
|
[35] |
Dai X, Zeng Z, Fu C, et al. Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury[J]. Crit Care, 2015, 19(1): 223.
|
[36] |
Donadello K, Scolletta S, Covajes C, et al. suPAR as a prognostic biomarker in sepsis[J]. BMC Med, 2012, 10: 2.
|
[37] |
Suberviola B, Castellanos-Ortega A, Ruiz RA, et al. Hospital mortality prognostication in sepsis using the new biomarkers;suPAR and proADM in a single determination on ICU admission[J]. Intensive Care Med, 2013, 39(11): 1945-1952.
|
[38] |
Huang Q, Xiong H, Yan P, et al. The Diagnostic and Prognostic Value of Supar in Patients With Sepsis: A Systematic Review and Meta-Analysis[J]. Shock, 2020, 53(4): 416-425.
|
[39] |
Koch A, Voigt S, Kruschinski C, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients[J]. Crit Care, 2011, 15(1): R63.
|
[40] |
de Pablo R, Monserrat J, Reyes E. Circulating sICAM-1 and sE-Selectin as biomarker of infection and prognosis in patients with systemic inflammatory response syndrome[J]. Eur J Intern Med, 2013, 24(2): 132-138.
|
[41] |
Kung CT, Hsiao SY, Su CM, et al. Serum adhesion molecules as predictors of bacteremia in adult severe sepsis patients at the emergency department[J]. Clin Chim Acta, 2013, 421: 116-120.
|
[42] |
Vassiliou AG, Mastora Z, Orfanos SE, et al. Elevated biomarkers of endothelial dysfunction/activation at ICU admission are associated with sepsis development[J]. Cytokine, 2014, 69(2): 240-247.
|
[43] |
Kjaergaard AG, Dige A, Nielsen JS, et al. The use of the soluble adhesion molecules sE-selectin, sICAM-1, sVCAM-1, sPECAM-1 and their ligands CD11a and CD49d as diagnostic and prognostic biomarkers in septic and critically ill non-septic ICU patients[J]. APMIS, 2016, 124(10): 846-855.
|
[44] |
David S, Mukherjee A, Ghosh CC, et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis[J]. Crit Care Med, 2012, 40(11): 3034-3041.
|
[45] |
Davis JS, Yeo TW, Piera KA, et al. Angiopoietin-2 is increased in sepsis and inversely associated with nitric oxide-dependent microvascular reactivity[J]. Crit Care, 2010, 14(3): R89.
|
[46] |
Ricciuto DR, dos Santos CC, Michael H, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis[J]. Crit Care Med, 2011, 39(4): 702-710.
|
[47] |
Leligdowicz A, Richard-Greenblatt M, Wright J, et al. Endothelial Activation: The Ang/Tie Axis in Sepsis[J]. Front Immunol, 2018, 9: 838.
|
[48] |
赵蓉,董士民. 血清endocan和降钙素原对脓毒症早期诊断及预后评估的临床价值[J]. 中华危重病急救医学,2017, 29(4): 321-326.
|
[49] |
García-Segarra G, Espinosa G, Tassies D, et al. Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent[J]. Intensive Care Med, 2007, 33(8): 1354-1362.
|
[50] |
黄彩芝,莫丽亚,邓永超,等. 抗凝血酶Ⅲ、D-二聚体和血小板检测在儿童脓毒症中的价值[J]. 临床儿科杂志,2013, 31(6): 530-532.
|
[51] |
Yang AP, Liu J, Yue LH, et al. Neutrophil CD64 combined with PCT, CRP and WBC improves the sensitivity for the early diagnosis of neonatal sepsis[J]. Clin Chem Lab Med, 2015, 54(2): 345-351.
|
[52] |
Edgar JDM, Gabriel V, Gallimore JR, et al. A prospective study of the sensitivity, specificity and diagnostic performance of soluble intercellular adhesion molecule 1, highly sensitive C-reactive protein, soluble E-selectin and serum amyloid A in the diagnosis of neonatal infection[J]. BMC Pediatr, 2010, 10: 22.
|
[53] |
Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections[J]. Crit Care, 2007, 11(2): R38.
|
[54] |
Gibot S, Béné MC, Noel R, et al. Combination biomarkers to diagnose sepsis in the critically ill patient[J]. Am J Respir Crit Care Med, 2012, 186(1): 65-71.
|
[55] |
Kofoed K, Eugen-Olsen J, Petersen J, et al. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor[J]. Eur J Clin Microbiol Infect Dis, 2008, 27(5): 375-383.
|
[56] |
Bauer PR, Kashyap R, League SC, et al. Diagnostic accuracy and clinical relevance of an inflammatory biomarker panel for sepsis in adult critically ill patients[J]. Diagn Microbiol Infect Dis, 2016, 84(2): 175-180.
|
[57] |
Shapiro NI, Trzeciak S, Hollander JE, et al. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis[J]. Crit Care Med, 2009, 37(1): 96-104.
|